GRMLGREENLAND MINES LTD
Is Greenland Mines struggling financially?
Yes, by its own account. Greenland Mines told the SEC on 29 Jun 2026, in Form 8-K, that there is substantial doubt about its ability to continue as a going concern.
Going concern disclosed Jun 2026
13/100
Critical
- Sector
- Biotech/Pharma
- Market cap
- $32.2M
- Source filing
- 8-K 29 Jun 2026
- Balance sheet
- 31 Mar 2026
Cash runway
-
7months
If the burn speeds up
Empty by Oct 2026
-
10months
If it eases off
Empty by Jan 2027
Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.
Out of cashTwo years or more
The runway math
Cash and short-term investments
$10.0M
÷
Cash burned over the last 12 months
$14.4M
What Greenland Mines told the SEC
…financial statements of the Company for the fiscal years ended December 31, 2025 and 2024 included an explanatory paragraph indicating that there was substantial doubt as to the Company’s ability to continue as a going concern. During the fiscal years ended December 31, 2025 and 2024 and the subsequent interim period through the date of this Current Report on Form 8-K, there were (a) no disagreements (as…
GREENLAND MINES LTD, Form 8-K, filed 29 Jun 2026.
Read the filing on SEC.govWhat this means
- Not a bankruptcy filing, and not a prediction.
- It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
- The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.
What else the numbers show
- 240.5% share-count increase The company issued stock. Each share now owns 70.6% less of the business than a year ago, before any change in the price.
- Cash burn is increasing It is spending 165% more cash per year than it was, so the runway above shortens even if nothing else changes.
Other Biotech/Pharma companies that filed the doubt
- VSTM Verastem $624.0M
- CRVO CervoMed $39.6M
- IMNN Imunon $9.2M
- CNXU Conexeu Sciences $237.9M
- CV CapsoVision $301.3M
- IBO Impact BioMedical $51.8M